COVID-19 and Gynecologic Oncology: What Have We Learned?
Opinion statement COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every c...
Gespeichert in:
Veröffentlicht in: | Current treatment options in oncology 2021-12, Vol.22 (12), p.117-117, Article 117 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 117 |
---|---|
container_issue | 12 |
container_start_page | 117 |
container_title | Current treatment options in oncology |
container_volume | 22 |
creator | Leibold, Aurora Papatla, Katyayani Zeligs, Kristen P. Blank, Stephanie V. |
description | Opinion statement
COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients. |
doi_str_mv | 10.1007/s11864-021-00905-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8609172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2601566063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</originalsourceid><addsrcrecordid>eNp9kctKAzEUhoMo1tsLuJABN26iJ_cZF4pUrUKhGy_LkGYy7cg0o0lb6Nubtt4XrnLC-c6XHH6EDgmcEgB1FgnJJcdACQYoQGCxgXaIYBxLqtTmsqYKU0WLDtqN8QWACg7FNuownhNaKLaD8u7g6f4akyIzvsx6C-9s27Sj2mYDv6oW59nz2EyzOzN32bPL-s4E78rLfbRVmSa6g49zDz3e3jx073B_0LvvXvWx5YpPcWmdcUoJUQ1LSRSrIC8oWCsJrxwjVtrSqJJDlW6Uq2FJh4blVc4KWZVOANtDF2vv62w4cUnnp8E0-jXUExMWujW1_t3x9ViP2rnOJRRE0SQ4-RCE9m3m4lRP6mhd0xjv2lnUVALhuaCwRI__oC_tLPi03ooSUoJkiaJryoY2xuCqr88Q0Mtg9DoYnYLRq2C0SENHP9f4GvlMIgFsDcTU8iMXvt_-R_sOf1aXOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2601566063</pqid></control><display><type>article</type><title>COVID-19 and Gynecologic Oncology: What Have We Learned?</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Leibold, Aurora ; Papatla, Katyayani ; Zeligs, Kristen P. ; Blank, Stephanie V.</creator><creatorcontrib>Leibold, Aurora ; Papatla, Katyayani ; Zeligs, Kristen P. ; Blank, Stephanie V.</creatorcontrib><description>Opinion statement
COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-021-00905-5</identifier><identifier>PMID: 34812973</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cancer ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - prevention & control ; COVID-19 - transmission ; Delivery of Health Care - standards ; Diagnosis ; Female ; Genital Neoplasms, Female - therapy ; Genital Neoplasms, Female - virology ; Gynecologic Cancers (LA Cantrell ; Gynecologic Cancers (LA Cantrell, Section Editor) ; Humans ; Infection Control - methods ; Medical diagnosis ; Medicine ; Medicine & Public Health ; Oncologists - standards ; Oncology ; Pandemics ; Patients ; Practice Patterns, Physicians' - standards ; SARS-CoV-2 - isolation & purification ; Section Editor ; Topical Collection on Gynecologic Cancers</subject><ispartof>Current treatment options in oncology, 2021-12, Vol.22 (12), p.117-117, Article 117</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</citedby><cites>FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</cites><orcidid>0000-0002-5333-9484 ; 0000-0001-9160-3939 ; 0000-0003-3372-0402 ; 0000-0003-4191-5154</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-021-00905-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-021-00905-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34812973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leibold, Aurora</creatorcontrib><creatorcontrib>Papatla, Katyayani</creatorcontrib><creatorcontrib>Zeligs, Kristen P.</creatorcontrib><creatorcontrib>Blank, Stephanie V.</creatorcontrib><title>COVID-19 and Gynecologic Oncology: What Have We Learned?</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement
COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.</description><subject>Cancer</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 - transmission</subject><subject>Delivery of Health Care - standards</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Genital Neoplasms, Female - therapy</subject><subject>Genital Neoplasms, Female - virology</subject><subject>Gynecologic Cancers (LA Cantrell</subject><subject>Gynecologic Cancers (LA Cantrell, Section Editor)</subject><subject>Humans</subject><subject>Infection Control - methods</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncologists - standards</subject><subject>Oncology</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Practice Patterns, Physicians' - standards</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>Section Editor</subject><subject>Topical Collection on Gynecologic Cancers</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctKAzEUhoMo1tsLuJABN26iJ_cZF4pUrUKhGy_LkGYy7cg0o0lb6Nubtt4XrnLC-c6XHH6EDgmcEgB1FgnJJcdACQYoQGCxgXaIYBxLqtTmsqYKU0WLDtqN8QWACg7FNuownhNaKLaD8u7g6f4akyIzvsx6C-9s27Sj2mYDv6oW59nz2EyzOzN32bPL-s4E78rLfbRVmSa6g49zDz3e3jx073B_0LvvXvWx5YpPcWmdcUoJUQ1LSRSrIC8oWCsJrxwjVtrSqJJDlW6Uq2FJh4blVc4KWZVOANtDF2vv62w4cUnnp8E0-jXUExMWujW1_t3x9ViP2rnOJRRE0SQ4-RCE9m3m4lRP6mhd0xjv2lnUVALhuaCwRI__oC_tLPi03ooSUoJkiaJryoY2xuCqr88Q0Mtg9DoYnYLRq2C0SENHP9f4GvlMIgFsDcTU8iMXvt_-R_sOf1aXOA</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Leibold, Aurora</creator><creator>Papatla, Katyayani</creator><creator>Zeligs, Kristen P.</creator><creator>Blank, Stephanie V.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5333-9484</orcidid><orcidid>https://orcid.org/0000-0001-9160-3939</orcidid><orcidid>https://orcid.org/0000-0003-3372-0402</orcidid><orcidid>https://orcid.org/0000-0003-4191-5154</orcidid></search><sort><creationdate>20211201</creationdate><title>COVID-19 and Gynecologic Oncology: What Have We Learned?</title><author>Leibold, Aurora ; Papatla, Katyayani ; Zeligs, Kristen P. ; Blank, Stephanie V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 - transmission</topic><topic>Delivery of Health Care - standards</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Genital Neoplasms, Female - therapy</topic><topic>Genital Neoplasms, Female - virology</topic><topic>Gynecologic Cancers (LA Cantrell</topic><topic>Gynecologic Cancers (LA Cantrell, Section Editor)</topic><topic>Humans</topic><topic>Infection Control - methods</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncologists - standards</topic><topic>Oncology</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Practice Patterns, Physicians' - standards</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>Section Editor</topic><topic>Topical Collection on Gynecologic Cancers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leibold, Aurora</creatorcontrib><creatorcontrib>Papatla, Katyayani</creatorcontrib><creatorcontrib>Zeligs, Kristen P.</creatorcontrib><creatorcontrib>Blank, Stephanie V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leibold, Aurora</au><au>Papatla, Katyayani</au><au>Zeligs, Kristen P.</au><au>Blank, Stephanie V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 and Gynecologic Oncology: What Have We Learned?</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>22</volume><issue>12</issue><spage>117</spage><epage>117</epage><pages>117-117</pages><artnum>117</artnum><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion statement
COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34812973</pmid><doi>10.1007/s11864-021-00905-5</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-5333-9484</orcidid><orcidid>https://orcid.org/0000-0001-9160-3939</orcidid><orcidid>https://orcid.org/0000-0003-3372-0402</orcidid><orcidid>https://orcid.org/0000-0003-4191-5154</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1527-2729 |
ispartof | Current treatment options in oncology, 2021-12, Vol.22 (12), p.117-117, Article 117 |
issn | 1527-2729 1534-6277 1534-5277 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8609172 |
source | MEDLINE; Springer Online Journals |
subjects | Cancer Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - prevention & control COVID-19 - transmission Delivery of Health Care - standards Diagnosis Female Genital Neoplasms, Female - therapy Genital Neoplasms, Female - virology Gynecologic Cancers (LA Cantrell Gynecologic Cancers (LA Cantrell, Section Editor) Humans Infection Control - methods Medical diagnosis Medicine Medicine & Public Health Oncologists - standards Oncology Pandemics Patients Practice Patterns, Physicians' - standards SARS-CoV-2 - isolation & purification Section Editor Topical Collection on Gynecologic Cancers |
title | COVID-19 and Gynecologic Oncology: What Have We Learned? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A15%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20and%20Gynecologic%20Oncology:%20What%20Have%20We%20Learned?&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Leibold,%20Aurora&rft.date=2021-12-01&rft.volume=22&rft.issue=12&rft.spage=117&rft.epage=117&rft.pages=117-117&rft.artnum=117&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-021-00905-5&rft_dat=%3Cproquest_pubme%3E2601566063%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2601566063&rft_id=info:pmid/34812973&rfr_iscdi=true |